Investment Thesis
Amgen demonstrates exceptional fundamental strength with robust revenue growth of 10% YoY, exceptional profitability (21% net margin, 24.7% operating margin), and strong free cash flow generation of $8.1B. The company's operating performance is outstanding, evidenced by 88.5% YoY net income growth and ROE of 89.1%, indicating highly efficient capital deployment despite leverage headwinds.
AMGN Strengths
- Exceptional profitability: 21% net margin and 24.7% operating margin demonstrate pricing power and operational efficiency in biologics
- Strong cash generation: $10B operating cash flow and $8.1B free cash flow provide financial flexibility and capital return capacity
- Robust revenue growth: 10% YoY growth combined with 88.5% net income growth shows operational leverage and improving execution
- High return on equity: 89.1% ROE demonstrates superior capital efficiency despite high leverage, suggesting strong asset quality and earnings power
AMGN Risks
- High leverage: 6.31x debt-to-equity ratio and $54.6B long-term debt creates financial risk, requiring sustained cash flow to service obligations
- Weak liquidity metrics: 1.14x current ratio and 0.90x quick ratio indicate tight short-term liquidity relative to current liabilities
- Thin interest coverage: 3.3x interest coverage is adequate but leaves limited margin for earnings deterioration or rate increases
- Biological products sector risk: Pipeline dependency and regulatory/patent cliff risks inherent to biopharmaceutical business model
Key Metrics to Watch
- Free cash flow sustainability and ability to reduce debt-to-equity below 5.0x
- Revenue growth trajectory and product pipeline clinical/commercial success
- Operating margin maintenance as revenue scales and competitive pressures evolve
- Quarterly cash flow trends and capital allocation decisions (debt reduction vs. shareholder returns)
AMGN Financial Metrics
Revenue
$36.8B
Net Income
$7.7B
EPS (Diluted)
$14.23
Free Cash Flow
$8.1B
Total Assets
$90.6B
Cash Position
$9.1B
AMGN Profitability Ratios
Gross Margin
12.9%
Operating Margin
24.7%
Net Margin
21.0%
ROE
89.1%
ROA
8.5%
FCF Margin
22.0%
AMGN Balance Sheet & Liquidity
Current Ratio
1.14x
Quick Ratio
0.90x
Debt/Equity
6.31x
Debt/Assets
0.0%
Interest Coverage
3.30x
Long-term Debt
$54.6B
Disclaimer: This analysis is generated by Claude AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: Mar 17, 2026 |
Data as of: 2025-12-31 |
Powered by Claude AI